MDS-736: Preliminary Efficacy and Safety Analysis of the MAXILUS Study of Luspatercept (LUSPA) Initiated at the Maximum Approved Dose in Transfusion-Dependent (TD) Lower-Risk Myelodysplastic Syndromes (LR-MDS) | Publicación